A Phase 3 Randomized Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
Brief description of study
If you have been diagnosed with liver cancer (hepatocellular carcinoma) diagnosed for the first time and have undergone hepatic resection or ablation, you may qualify for this Phase 3 study. The main goal of this study is to test the safety and how effective of an investigational drug called nivolumab (also known as BMS-936558 or OPDIVO®) for patients with liver cancer after hepatic resection or ablation in order to prevent disease recurrence.
Clinical Study Identifier: s17-01298
ClinicalTrials.gov Identifier: NCT03383458
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
